CPDR is a comprehensive research program to study prostate cancer and prostate disease, CPDR was established in 1992 (Public Law 102-172). The program’s mission is fulfilled primarily through its three principal programs: (1) the Clinical Translational Research Center; (2) the Basic Science Research Program, and (3) the Tri-Service Multicenter Prostate Cancer Database to encompass its clinical research work with participating military medical centers.
The Clinical Translational Research Center
A prostate cancer clinical trials center at Walter Reed National Military Medical Center (WRNMMC). Recognizing that too few men have participated in clinical trials in the past, this Center will make state-of-the-art research trials available to deserving military health beneficiaries. The Center is open to all beneficiaries worldwide.
Basic Science Research Program
The only free-standing prostate cancer research center in the U.S. This 20,000 square foot state-of-the-art basic science laboratory facility is attracting the best and brightest to study the disease. Using blood and tissues collected from volunteering military beneficiaries, the CPDR laboratory has amassed a large bank of prostate cancer specimens that are serving to unravel the genetics of the disease.
Tri-Service Multicenter Prostate Cancer Database
The largest, most comprehensive prostate cancer database in the United States. Involving the Army, Air Force, and Navy at multiple military medical centers, the program is a model for interservice cooperation and research collaboration. With approximately 26,000 prostate cancer survivors enrolled to date, the CPDR database is rapidly becoming a national resource.
The information on this web site is not intended to replace medical advice. You should review the information carefully with your physician(s) before adopting any of this information into your current medical plan. CPDR provides clinical and research information that is complete and in accord with the standards in existence at the time of publication. However, CPDR does not warrant that the information contained herein is in every respect accurate or complete and CPDR is not responsible for any errors or omissions or for the results obtained from the use of this information. CPDR makes no representations or warranties with resect to any treatment, action, process or application of medication by any person following the information provided by CPDR. CPDR will not be liable for any damages arising from the use of this information.
The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Department or Defense.
Please consult with your doctor before adopting any of the information found on this site into your current healthcare plan.
CPDR WEEKLY SEMINAR
Alagarsamy Srinivasan, PhD
Assistant Director, BSRP
Presentation: "Liquid Biopsy in Prostate Cancer"
Date: April 28, 2017
Time: 11:00 am -12:00 pm
Location: CPDR, Rockville, MD
2nd floor conference room
Guest Speaker Program
Dr. Robert Dean
Director of Andrology
Walter Reed National Military Medical Center
Presentation: “Prostate Cancer Survivorship: Sexual Health Therapies”
Date: Thursday 4 May 2017
Location: Walter Reed National Military Medical Center (America Building, 2nd floor, Room 2525) and Fort Belvoir Community Hospital (via video teleconference in Oaks Pavilion, 1st floor, Room 332).
A military ID card is required to get on base at Walter Reed. Attendees without a military ID need to call the Prostate Center at 301-319-2900 at least 4 business days in advance to complete paperwork for gate access approval. Also bring some form of picture identification at the gate.
Read the May 2017 WRNMMC UsToo! Newsletter
Read the April 2017 CPDR E-Newsletter
April 7, 2017
Highlights at the 2017 AACR Annual Meeting in Washington, D.C.
The Center for Prostate Disease Research (CPDR) multi-disciplinary team - together with collaborators - presented 8 abstracts in moderated poster presentations at the American Association of Cancer Researchers Annual Meeting, April 1-5, 2016, Wasahington, DC. The team was co-led by Dr. Shiv Srivastava, CPDR Co-Director and Professor in the Department of Surgery at USU and WRNMMC and Dr. Albert Dobi, Associate Director, CPDR and Research Assistant Professor, Department of Surgery , USU and WRNMMC.
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag
Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.
Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer
Eur Urol. 2017 Jan 5. pii: S0302-2838(16)30922-8. doi: 10.1016/j.eururo.2016.12.018. [Epub ahead of print]